Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABIGAIL: abemaciclib plus endocrine therapy versus chemotherapy as initial treatment for high-burden visceral ER-positive/HER2-negative metastatic breast cancer
2019-000260-14Phase 3Active
- Sponsor
- Unicancer
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of abemaciclib, anastrozole, letrozole, fulvestrant, paclitaxel and 1 more in breast cancer (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival within 24 weeks. Started Feb 2020; status: active.
02
Drugs
abemaciclibanastrozoleletrozolefulvestrantpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-000260-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000260-14.